Viking Therapeutics Poised for Potential Breakthrough in Obesity Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VKTX?
Source: Fool
- Intensifying Market Competition: The anti-obesity drug market is becoming increasingly competitive as more healthcare companies develop GLP-1 drugs, with potential market shares reaching billions of dollars, prompting companies to expedite their drug approval processes.
- Clinical Trial Progress: Viking Therapeutics is conducting a key clinical trial for VK2735, with results expected in the third quarter of this year; if positive, this could significantly boost the company's stock price and enhance its competitive position in the market.
- Maintenance Dose Research: Based on promising early data, Viking is assessing the potential of VK2735 for maintenance dosing, testing it as a monthly injection and daily or weekly oral medication, which could offer patients a more competitive pricing option if successful.
- Financial Challenges: Despite the promising outlook for VK2735, Viking Therapeutics has yet to generate revenue and incurred a net loss of $359.6 million last year, necessitating cautious consideration of risks versus potential returns for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.330
Low
70.00
Averages
97.00
High
125.00
Current: 32.330
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking's VK2735 Drug Advances in Clinical Trials
- Clinical Trial Progress: Viking Therapeutics is conducting multiple clinical trials for its GLP-1 drug VK2735, evaluating its potential as a monthly maintenance dose, which could significantly enhance its market competitiveness if successful.
- Intensifying Market Competition: With numerous healthcare companies developing GLP-1 drugs, the competition for market share is fierce, with potential revenues reaching billions, necessitating Viking to expedite its market entry to capture share.
- Key Data Release: Viking expects to announce critical clinical trial results for VK2735 in the third quarter of this year; if the data is promising, it could lead to a stock price surge and increased investor interest.
- Financial Challenges: Despite the positive outlook for VK2735, Viking has yet to generate revenue, reporting a net loss of $359.6 million in 2025, and its stock has declined 24% from its 52-week high, indicating significant financial pressure.
See More
Viking Therapeutics Poised for Potential Breakthrough in Obesity Drug Market
- Intensifying Market Competition: The anti-obesity drug market is becoming increasingly competitive as more healthcare companies develop GLP-1 drugs, with potential market shares reaching billions of dollars, prompting companies to expedite their drug approval processes.
- Clinical Trial Progress: Viking Therapeutics is conducting a key clinical trial for VK2735, with results expected in the third quarter of this year; if positive, this could significantly boost the company's stock price and enhance its competitive position in the market.
- Maintenance Dose Research: Based on promising early data, Viking is assessing the potential of VK2735 for maintenance dosing, testing it as a monthly injection and daily or weekly oral medication, which could offer patients a more competitive pricing option if successful.
- Financial Challenges: Despite the promising outlook for VK2735, Viking Therapeutics has yet to generate revenue and incurred a net loss of $359.6 million last year, necessitating cautious consideration of risks versus potential returns for investors.
See More
Comparative Analysis of Bitcoin and Viking Investments
- Viking Drug Development Progress: Viking Therapeutics' lead candidate VK2735 has shown significant weight reduction in phase 2 trials with a tolerable side effect profile, and is expected to enter phase 3 trials in Q3 2026, potentially paving the way for FDA approval and a subsequent stock price surge.
- Market Competition Pressure: Despite Viking's potential in the anti-obesity drug market, competitors like Novo Nordisk and Eli Lilly have established a strong foothold, posing a threat to Viking's market share, and failure to secure clinical approval could lead to a severe drop in stock price.
- Bitcoin's Growth Potential: Bitcoin's value is primarily driven by supply constraints, with recent capital inflows into U.S. spot Bitcoin ETFs reaching $614 million and cumulative inflows around $57 billion, indicating strong market demand that could continue to drive prices higher.
- Investment Choice Analysis: For a $1,500 investment, Viking could yield high returns if it successfully enters the market, but it faces multiple uncertainties, whereas Bitcoin, despite short-term volatility, has a clearer growth trajectory, making it suitable for investors who have not yet diversified their portfolios.
See More
Investment Outlook for Viking Therapeutics and Bitcoin
- Clinical Trial Progress: Viking Therapeutics' lead candidate VK2735 has shown significant weight loss in phase 2 trials with a tolerable side effect profile, and the company has initiated two phase 3 studies, with the oral formulation expected to enter trials in Q3 2026; positive results could accelerate FDA approval and unlock substantial market potential.
- Strong Financial Position: The company holds $706 million in cash and short-term investments, sufficient to cover its $393 million annual operating expenses, ensuring financial stability until more clinical data is available, and if results remain positive, the stock price could see significant appreciation.
- Intense Market Competition: Viking's weight-loss treatment will face competition from established players like Novo Nordisk and Eli Lilly, which have already launched approved oral weight-loss drugs, potentially impacting Viking's market share and shareholder returns.
- Bitcoin Investment Potential: In contrast, Bitcoin's growth does not rely on clinical data or regulatory approvals, with its value primarily driven by supply and demand dynamics; recent capital inflows into U.S. spot Bitcoin ETFs reached $614 million, indicating strong market demand, and despite its volatility, long-term supply constraints are likely to drive price increases.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
Viking's VK2735 Drug Advances in Clinical Trials
- Clinical Trial Progress: Viking Therapeutics is conducting multiple clinical trials for its GLP-1 drug VK2735, evaluating its potential as a monthly maintenance dose, which could significantly enhance its market competitiveness if successful.
- Intensifying Market Competition: With numerous healthcare companies developing GLP-1 drugs, the competition for market share is fierce, with potential revenues reaching billions, necessitating Viking to expedite its market entry to capture share.
- Key Data Release: Viking expects to announce critical clinical trial results for VK2735 in the third quarter of this year; if the data is promising, it could lead to a stock price surge and increased investor interest.
- Financial Challenges: Despite the positive outlook for VK2735, Viking has yet to generate revenue, reporting a net loss of $359.6 million in 2025, and its stock has declined 24% from its 52-week high, indicating significant financial pressure.
See More
Viking Therapeutics Poised for Potential Breakthrough in Obesity Drug Market
- Intensifying Market Competition: The anti-obesity drug market is becoming increasingly competitive as more healthcare companies develop GLP-1 drugs, with potential market shares reaching billions of dollars, prompting companies to expedite their drug approval processes.
- Clinical Trial Progress: Viking Therapeutics is conducting a key clinical trial for VK2735, with results expected in the third quarter of this year; if positive, this could significantly boost the company's stock price and enhance its competitive position in the market.
- Maintenance Dose Research: Based on promising early data, Viking is assessing the potential of VK2735 for maintenance dosing, testing it as a monthly injection and daily or weekly oral medication, which could offer patients a more competitive pricing option if successful.
- Financial Challenges: Despite the promising outlook for VK2735, Viking Therapeutics has yet to generate revenue and incurred a net loss of $359.6 million last year, necessitating cautious consideration of risks versus potential returns for investors.
See More
Comparative Analysis of Bitcoin and Viking Investments
- Viking Drug Development Progress: Viking Therapeutics' lead candidate VK2735 has shown significant weight reduction in phase 2 trials with a tolerable side effect profile, and is expected to enter phase 3 trials in Q3 2026, potentially paving the way for FDA approval and a subsequent stock price surge.
- Market Competition Pressure: Despite Viking's potential in the anti-obesity drug market, competitors like Novo Nordisk and Eli Lilly have established a strong foothold, posing a threat to Viking's market share, and failure to secure clinical approval could lead to a severe drop in stock price.
- Bitcoin's Growth Potential: Bitcoin's value is primarily driven by supply constraints, with recent capital inflows into U.S. spot Bitcoin ETFs reaching $614 million and cumulative inflows around $57 billion, indicating strong market demand that could continue to drive prices higher.
- Investment Choice Analysis: For a $1,500 investment, Viking could yield high returns if it successfully enters the market, but it faces multiple uncertainties, whereas Bitcoin, despite short-term volatility, has a clearer growth trajectory, making it suitable for investors who have not yet diversified their portfolios.
See More
Investment Outlook for Viking Therapeutics and Bitcoin
- Clinical Trial Progress: Viking Therapeutics' lead candidate VK2735 has shown significant weight loss in phase 2 trials with a tolerable side effect profile, and the company has initiated two phase 3 studies, with the oral formulation expected to enter trials in Q3 2026; positive results could accelerate FDA approval and unlock substantial market potential.
- Strong Financial Position: The company holds $706 million in cash and short-term investments, sufficient to cover its $393 million annual operating expenses, ensuring financial stability until more clinical data is available, and if results remain positive, the stock price could see significant appreciation.
- Intense Market Competition: Viking's weight-loss treatment will face competition from established players like Novo Nordisk and Eli Lilly, which have already launched approved oral weight-loss drugs, potentially impacting Viking's market share and shareholder returns.
- Bitcoin Investment Potential: In contrast, Bitcoin's growth does not rely on clinical data or regulatory approvals, with its value primarily driven by supply and demand dynamics; recent capital inflows into U.S. spot Bitcoin ETFs reached $614 million, indicating strong market demand, and despite its volatility, long-term supply constraints are likely to drive price increases.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
